Covista Inc.(CVSA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #222 of 2,879 stocksTOP 10%
View Consumer Discretionary peers →
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CVSA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Covista Inc. (CVSA), a Consumer Discretionary sector company. 13F Pro's AI-powered ranking engine scores CVSA at 72.6/100 on a 32-signal composite quality model, placing it at rank #222 of 2,879 stocks — the top 10% of the AI-ranked universe. CVSA scores in the top quartile across balance sheet strength (83.9), free cash flow (83.0), earnings quality (81.5). Shareholder dilution risk is elevated at 38.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Covista Inc. reports quarterly revenue of $487.0M, net income of $41.6M, an operating margin of 18.8%. Top institutional holders of CVSA by reported 13-F value include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CVSA trades on the NYSE exchange and files with the SEC under CIK 730464. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Covista Inc. directly from SEC EDGAR. Covista Inc.'s 13F Pro composite quality score has ranged between 60 and 73 since 2024, currently 72.6 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.
What's Driving CVSA's Business? Latest 10-Q Breakdown
AI-extracted from Covista Inc.'s 10-Q filed 2026-05-07 — Q3 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q3 revenue increased 4.5% to $487.0M; net income fell 31.6% to $41.6M, pressured by discontinued operations losses and higher costs despite enrollment growth across all segments.
Biggest Revenue Drivers
Total revenue: $487.0M+4.5% YoY
Enrollment increased 12.3% YoY; higher tuition rates and increased average credit hours per student offset by $18.0M revenue shift to Q2 due to academic calendar shift.
Higher tuition rates and increased March session enrollment; pre-licensure nursing growth offset post-licensure declines.
Enrollment increased 4.1% YoY for January semester; higher tuition rates and pricing increases effective September 2025.
Largest Expense Items
Increased labor and other costs to support higher enrollment.
Increased marketing expense and investments to support growth initiatives; lower asset impairments vs prior year partially offset increases.
Loss on debt extinguishment from write-off of debt issuance costs related to Term Loan B amendment and Senior Secured Notes repayment.
Margins: Operating margin remained flat at 18.8% YoY despite revenue growth; adjusted operating margin declined to 21.0% from 22.6% YoY, primarily driven by increased labor costs and marketing investments to support enrollment growth, partially offset by cost efficiencies and reduced asset impairments.
Watch Items from the Filing
- Composite financial responsibility score declined to 0.2 (below 1.5 threshold) as of FY2022; institutions operating under provisional Title IV certification with heightened cash monitoring and $202.6M letters of credit outstanding (10% of FY2025 Title IV funds).
- Loss from discontinued operations of $16.3M in Q3 FY2026 vs $0.04M income in prior year, driven by ongoing litigation and settlement costs related to DeVry University divestiture.
- Walden adjusted operating income decreased 11.7% YoY in Q3 despite strong nine-month growth of 29.3%, partially due to $18.0M revenue timing shift to Q2; segment margin compressed to 22.7% from 26.9% YoY.
- Chamberlain post-licensure nursing enrollment declining throughout FY2026 despite pre-licensure growth; nine-month adjusted operating income down 8.8% YoY despite 3.4% revenue growth.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q3 2026
$487.0M
Net Income
Q3 2026
$41.6M
Free Cash Flow
Q3 2026
$165.9M
Operating Margin
Q3 2026
18.8%
D/E Ratio
Q3 2026
0.37
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+12.9% YoYNet Income
+73.3% YoYOperating Income
+57.4% YoYEPS (Diluted)
+82.3% YoYTotal Assets
+0.4% YoYTotal Debt
-14.8% YoYOp. Cash Flow
+14.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.79B +12.9% | $1.58B +9.2% | $1.45B +5.0% | $1.38B +53.7% | $899.2M +3.8% | $866.4M |
| Net Income | $237.1M +73.3% | $136.8M +46.5% | $93.4M -70.0% | $311.0M +344.1% | $70.0M +182.1% | $-85.3M |
| Operating Income | $341.5M +57.4% | $217.1M +29.1% | $168.2M +119.1% | $76.7M -30.5% | $110.4M +0.3% | $110.1M |
| EPS (Diluted) | $6.18 +82.3% | $3.39 +65.4% | $2.05 -68.1% | $6.43 +372.8% | $1.36 +186.1% | $-1.58 |
| Total Assets | $2.75B +0.4% | $2.74B -2.5% | $2.81B -7.3% | $3.03B -1.8% | $3.08B +36.6% | $2.26B |
| Total Debt | $552.7M -14.8% | $648.7M -6.7% | $695.1M -17.1% | $838.9M -21.9% | $1.07B +267.6% | $292.1M |
| Operating Cash Flow | $337.9M +14.2% | $295.8M +54.1% | $191.9M +1710.3% | $10.6M -94.5% | $192.2M +78.5% | $107.7M |
AI Insight: CVSA Financial Trends
Revenue growth accelerated to 12% year-over-year in Q4 2025 but profitability declined in Q1 2026 with net income dropping 31% sequentially.
• Revenue grew from $410M in Q2 2024 to $487M in Q1 2026, with Q4 2025 hitting $503M peak.
• Total debt decreased from $649M in Q2 2024 to $503M in Q1 2026, reducing leverage.
• Operating cash flow remains volatile, swinging from -$19M in Q4 2024 to $208M in Q1 2025.
⚠ Net income dropped to $42M in Q1 2026 from $76M in Q4 2025, the lowest in four quarters.
⚠ Sequential revenue decline of 3% from Q4 2025 to Q1 2026 breaks momentum after strong Q4 performance.
Get alerted when CVSA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Covista Inc. including:
Top Institutional Holders of CVSA
BlackRock, Inc.
$602.7M5,229,508 shFMR LLC
$305.9M2,654,244 shVANGUARD PORTFOLIO MANAGEMENT LLC
$279.1M2,421,606 shARIEL INVESTMENTS, LLC
$222.6M1,931,284 shDIMENSIONAL FUND ADVISORS LP
$204.4M1,773,564 shVANGUARD CAPITAL MANAGEMENT LLC
$171.8M1,490,536 shSTATE STREET CORP
$155.5M1,349,338 shCapital World Investors
$118.6M1,029,363 shGEODE CAPITAL MANAGEMENT, LLC
$98.4M854,009 shWELLINGTON MANAGEMENT GROUP LLP
$94.1M816,298 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $602.7M | 5,229,508 |
| FMR LLC | $305.9M | 2,654,244 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $279.1M | 2,421,606 |
| ARIEL INVESTMENTS, LLC | $222.6M | 1,931,284 |
| DIMENSIONAL FUND ADVISORS LP | $204.4M | 1,773,564 |
| VANGUARD CAPITAL MANAGEMENT LLC | $171.8M | 1,490,536 |
| STATE STREET CORP | $155.5M | 1,349,338 |
| Capital World Investors | $118.6M | 1,029,363 |
| GEODE CAPITAL MANAGEMENT, LLC | $98.4M | 854,009 |
| WELLINGTON MANAGEMENT GROUP LLP | $94.1M | 816,298 |
More Consumer Discretionary Companies
View all Consumer Discretionary →Put CVSA on your watchlist
Track score changes the day Covista Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CVSA a good stock to buy?
13F Pro's AI-powered analysis of Covista Inc. (CVSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Discretionary sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVSA are available on the CVSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CVSA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Covista Inc.'s investment landscape.